MRI abnormalities in children following sequential chemotherapy, hyperfractionated accelerated radiotherapy and high-dose thiotepa for high-risk primitive neuroectodermal tumours of the central nervous system

被引:9
|
作者
Thust, Stefanie C. [1 ,3 ]
Blanco, Esther [2 ]
Michalski, Antony J. [2 ]
Chong, W. K. [1 ]
Gaze, Mark N. [2 ,3 ]
Phipps, Kim [2 ]
Mankad, Kshitij [1 ]
机构
[1] Great Ormond St Hosp Children NHS Fdn Trust, Dept Paediat Neuroradiol, London, England
[2] Great Ormond St Hosp Children NHS Fdn Trust, Dept Paediat Oncol, London, England
[3] Univ Coll London Hosp NHS Fdn Trust, Dept Oncol, London, England
关键词
cerebral primitive neuroectodermal tumour; chemotherapy; medulloblastoma; paediatrics; radiation oncology; thiotepa; WHITE-MATTER; BRAIN-TUMORS; RADIATION-THERAPY; CRANIOSPINAL RADIOTHERAPY; MEDULLOBLASTOMA; CHILDHOOD; PSEUDOPROGRESSION; SURVIVORS; INJURY; TRIAL;
D O I
10.1111/1754-9485.12232
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: Intensive postsurgical therapies have improved survival in children with primitive neuroectodermal tumour, but there is concern that the combination of chemotherapy and radiotherapy may result in a compound injury to normal brain. The purposes of this analysis were to characterise what types of imaging abnormalities occur, identify risk factors and explore how treatment-related changes may be distinguished from tumour. Method: One hundred fifty-three MRI studies in 14 children treated with sequential chemotherapy, hyperfractionated accelerated radiotherapy and high-dose thiotepa were retrospectively analysed at a paediatric national referral centre. Results: We observed 11 episodes of new focal enhancing lesions, 5 of which were transient and judged to be treatment related. In addition, 7/14 (50%) of children demonstrated moderate to severe brain volume loss featuring a leukodystrophy pattern. Conclusion: Treatment-related brain MRI abnormalities occurred frequently in this series with a risk of misdiagnosis as tumour. A proportion of patients suffer generalised white matter injury, which has not been appreciated as a side effect of this particular therapy.
引用
收藏
页码:683 / 690
页数:8
相关论文
共 50 条
  • [21] High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors
    Pérez-Martínez, A
    Lassaletta, A
    González-Vicent, M
    Sevilla, J
    Díaz, MA
    Madero, L
    JOURNAL OF NEURO-ONCOLOGY, 2005, 71 (01) : 33 - 38
  • [22] Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma
    Massimino, M
    Gandola, L
    Luksch, R
    Spreafico, F
    Riva, D
    Solero, C
    Giangaspero, F
    Locatelli, F
    Podda, M
    Bozzi, F
    Pignoli, E
    Collini, P
    Cefalo, G
    Zecca, M
    Casanova, M
    Ferrari, A
    Terenziani, M
    Meazza, C
    Polastri, D
    Scaramuzza, D
    Ravagnani, F
    Fossati-Bellani, F
    NEURO-ONCOLOGY, 2005, 7 (01) : 41 - 48
  • [23] Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors
    Choi, L. Mi Rim
    Rood, Brian
    Kamani, Naynesh
    La Fond, Deborah
    Packer, Roger J.
    Santi, Maria Rita
    MacDonald, Tobey J.
    PEDIATRIC BLOOD & CANCER, 2008, 50 (05) : 970 - 975
  • [24] SALVAGE HIGH-DOSE CHEMOTHERAPY FOR PATIENTS WITH RECURRENT CENTRAL NERVOUS SYSTEM GERM-CELL TUMOURS
    Yanagisawa, Takaaki
    Fukuoka, Kohei
    Suzuki, Tomonari
    Yamaoka, Masanori
    Yamaoka, Wataru
    Yokoi, Kentaro
    Akiyama, Masaharu
    Masumoto, Ai
    Nonaka, Yuichiro
    Adachi, Junichi
    Mishima, Kazuhiko
    Nisikawa, Ryo
    NEURO-ONCOLOGY, 2016, 18 : 44 - 45
  • [25] High-dose chemotherapy with thiotepa, cyclophosphamide and etoposide in high-risk Ewing sarcoma family tumours paediatric patients: single-centre experience
    Ilari, I.
    De Ioris, M. A.
    Pessolano, R.
    Castellano, A.
    Serra, A.
    Jenkner, A.
    De Sio, L.
    Cozza, R.
    Fidani, P.
    De Laurentis, C.
    Donfrancesco, A.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S82 - S82
  • [26] LONG TERM FOLLOW-UP OF PATIENTS WITH METASTATIC (M plus ) AND HIGH-RISK MEDULLOBLASTOMA WITH TAILORED-DOSES HYPERFRACTIONATED ACCELERATED RADIOTHERAPY (HART) CSI PLUS/MINUS HIGH-DOSE THIOTEPA
    Massimino, M.
    Gandola, L.
    Spreafico, F.
    Biassoni, V.
    Schiavello, E.
    Pecori, E.
    Pignoli, E.
    Giandini, T.
    Luksch, R.
    Casanova, M.
    Ferrari, A.
    Terenziani, M.
    Poggi, G.
    Podda, M.
    Meazza, C.
    Catania, S.
    Chiaravalli, S.
    Puma, N.
    Boschetti, L.
    Veneroni, L.
    Antonelli, M.
    Buttarelli, F.
    Giangaspero, F.
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S279 - S279
  • [27] A PHASE-I PHASE-II PILOT-STUDY EMPLOYING HYPERFRACTIONATED RADIOTHERAPY AND ADJUVANT CHEMOTHERAPY FOR HIGH-RISK PRIMITIVE NEUROECTODERMAL TUMORS
    ALLEN, JC
    NIRENBERG, A
    DONAHUE, B
    ANNALS OF NEUROLOGY, 1991, 30 (03) : 457 - 458
  • [28] Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery
    Kushner, BH
    Wolden, S
    LaQuaglia, MP
    Kramer, K
    Verbel, D
    Heller, G
    Cheung, NKV
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (11) : 2821 - 2828
  • [29] High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors
    Papadakis, V
    Dunkel, IJ
    Cramer, LD
    Kramer, E
    Papadopoulos, E
    Goldman, S
    Packer, RJ
    Willoughby, M
    Baker, D
    Garvin, J
    Strandjord, S
    Coccia, P
    Kaplan, AM
    Klemperer, M
    Finlay, JL
    BONE MARROW TRANSPLANTATION, 2000, 26 (02) : 153 - 160
  • [30] White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor
    Fouladi, M
    Chintagumpala, M
    Laningham, FH
    Ashley, D
    Kellie, SJ
    Langston, JW
    McCluggage, CW
    Woo, S
    Kocak, M
    Krull, K
    Kun, LE
    Mulhern, RK
    Gajjar, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (22) : 4551 - 4560